Researchers at Rutgers University-New Brunswick (N.J.), biotechnology company Naicons, NeED Pharmaceuticals and Italy-based universities, discovered the antibiotic, called pseudouridimycin. The research team published their findings in Cell. They discovered the antibiotic while screening microbes from soil samples found in Italy.
The antibiotic inhibits bacterial RNA polymerase, which is the enzyme responsible for bacterial RNA synthesis. It uses different mechanisms to inhibit the enzyme, including a binding site, as compared to rifampin, the antibiotic most commonly used to inhibit bacterial RNA polymerase.
The antibiotic does not show any cross-resistance with rifampin, instead, it works as a complement to rifampin. It has a “spontaneous resistance rate that is just one-tenth the spontaneous resistance rate of rifampin,” the study shows. Additionally, pseudouridimycin inhibits only bacterial RNA polymerase but not human RNA polymerases.
“The discovery also underscores the importance of natural products in providing new antibiotics,” said Stefano Donadio, CEO of Naicons, who co-led the research. “Microbes have had had billions of years to develop ‘chemical weapons’ to kill other microbes.”
More articles on healthcare quality:
California hospital closes surgical unit after mold found in sterilization sink
AORN experts respond to study on bouffant use and SSI rates
Study links bacterial outbreak in hospital NICU to contaminated tap water
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.